Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
By A. Murat, E. Migliavacca, T. Gorlia, Wanyu L. Lambiv, T. Shay, M. Hamou, N. de Tribolet, L. Regli, Wolfgang Wick, M. Kouwenhoven and 10 more. Journal of Clinical Oncology, 2008
727 citations recorded by the source corpus.
Subfields: Genetics, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/d40a13b49ce55f10eb3515d852b39336a477dc36
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
- Michael Weller
- Guido Reifenberger
- Elizabeth Purdom
- Gad Getz
- Richard K. Wilson
- Terence P. Speed
- Stacey Gabriel
In Molecular Biology
- Jill P. Mesirov
- D. Hayes
- Matthew D. Wilkerson
- Pablo Tamayo
- Gad Getz
- Matthew Meyerson
- Katherine A. Hoadley
- Elizabeth Purdom
In Oncology
Citations in the corpus
- PrognoScan: a new database for meta-analysis of the prognostic value of genes (2009, background): “As of February 2009, the collection included more than 40 datasets of various cancer types spanning a wide range of cancers including bladder, blood, breast, brain, esophagus, head and neck, kidney, lung, and ovarian (Table 1) [ 10-35 ], far more comprehensive than both ITTACA, which focuses on blad”
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008, neutral): “Neuropathology: Ken Aldape(10), Darell Bigner(6), Tom Mikkelsen(8) & Scott VandenBerg(9).”
- An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 (2010, methodology): “…and gene expression profiling studies identifying gene signatures associated with EGFR overexpression, clinical features, and survival (Freije et al., 2004; Liang et al., 2005; Mischel et al., 2003; Murat et al., 2008; Nutt et al., 2003; Phillips et al., 2006; Shai et al., 2003; Tso et al., 2006).”
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, background): “14 Nevertheless, long-term survival can be observed even in the absence of MGMT promoter methylation, indicating that MGMT promoter methylation is only one aspect of a very complex biological system.(44,45) A study published this year proposed that the extent of MGMT methylation, as”